Bionano Genomics Inc. [NASDAQ: BNGO] traded at a low on 06/28/22, posting a -5.96 loss after which it closed the day’ session at $1.42. The company report on June 16, 2022 that Bionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Bionano will exhibit its solutions relevant to cancer research: the Saphyr® system, NxClinical™ software and expert laboratory services.
A corporate satellite presentation by Alicia Bertolotti, Bionano, Dr. Sylvia Genovese, Bambino Gesù Children’s Hospital, and Dr. Juan Díaz-Martín, Institute of Biomedicine of Sevilla (IBiS), will cover the use of OGM for clinical research applications in solid tumor analysis.
The results of the trading session contributed to over 4439527 shares changing hands. Over the past one week, the price volatility of Bionano Genomics Inc. stands at 8.80% while the volatility over the past one month is 8.26%.
The market cap for BNGO stock reached $393.57 million, with 284.61 million shares outstanding and 284.15 million shares in the current float. Compared to the average trading volume of 6.65M shares, BNGO reached a trading volume of 4439527 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $8.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 16, 2021. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 24, 2020, representing the official price target for Bionano Genomics Inc. stock. Previously, the target price had yet another raise to $1.50, while Oppenheimer analysts kept a Outperform rating on BNGO stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.13, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 19.20. The Price to Book ratio for the last quarter was 1.30, with the Price to Cash per share for the same quarter was set at 0.78.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.05. With this latest performance, BNGO shares dropped by -7.19% in over the last four-week period, additionally sinking by -57.36% over the last 6 months – not to mention a drop of -81.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 43.84, with the RSI for the last a single of trading hit 42.59, and the three-weeks RSI is set at 44.20 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 1.6039, while it was recorded at 1.5080 for the last single week of trading, and 3.0180 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -428.79 and a Gross Margin at +4.47. Bionano Genomics Inc.’s Net Margin is presently recorded at -402.84.
Return on Equity for this stock declined to -38.92, with Return on Assets sitting at -33.11.
Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.10 and a Current Ratio set at 13.00.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $110 million, or 25.80% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: BLACKROCK INC. with ownership of 18,595,630, which is approximately -0.346% of the company’s market cap and around 2.00% of the total institutional ownership; VANGUARD GROUP INC, holding 15,876,289 shares of the stock with an approximate value of $23.97 million in BNGO stocks shares; and STATE STREET CORP, currently with $11.66 million in BNGO stock with ownership of nearly 7.298% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 69 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 5,928,318 shares. Additionally, 78 investors decreased positions by around 9,244,166 shares, while 36 investors held positions by with 57,539,928 shares. The mentioned changes placed institutional holdings at 72,712,412 shares, according to the latest SEC report filing. BNGO stock had 21 new institutional investments in for a total of 1,697,905 shares, while 27 institutional investors sold positions of 3,375,036 shares during the same period.